Steqeyma is approved for adult and pediatric patients with plaque psoriasis and active psoriatic arthritis as well as adults with Crohn's disease and ulcerative colitis.
A Wolters Kluwer Health prediction report features 25 wide-ranging predictions spanning health AI, preventing burnout, tech for the next generation and more.
The drug is indicated for the treatment of HIV-1 infection and for pre-exposure prophylaxis to reduce the risk of HIV-1 infection in adults and adolescents.
